The Houston Angel Network's investors heard from growing startups in their portfolio — along with a few prospects. Getty Images

The Houston Angel Network checked in with their investors and portfolio companies at their biannual Houston Angel Summit that gathered HAN members, local investors, and startup founders for a day full of educational opportunities, pitches, and fireside chats.

The event, which took place last week at Rice University's Liu Idea Lab for Innovation and Entrepreneurship, featured 11 startups – both new and more familiar to HAN members – pitching their growing companies in hopes of catching the interest of potential investors.

BioMedical Music Solutions

Austin-based BioMedical Music Solutions has a SaaS platform that uses artificial intelligence and music to accelerate rehabilitation at a lower cost. Founder Hope Young explained her years-proven therapy can work its magic in one-third of the time and one-tenth of the cost of traditional physical therapy sessions.

Optelos

Houston-based Optelos has a patented SaaS solution that can transform physical asset images, videos, and documents into what's known as a "Digital Inspection Twin" that can enabling knowledge workers utilizing our unified data management, reality modeling, and in-process artificial intelligence solution, to digitally visualize, analyze and manage their entire asset base.

Pocket Naloxone

Maryland-based Pocket Naloxone is attempting to solve the opioid crisis. The company has a portfolio of over-the-counter drug overdose reversal agents, including a naloxone OTC product.

AI Driller

Houston-based AI Driller is using mathematic algorithms to apply automation on rigs for drilling. The startup can also offer its clients real-time data and cuts out the opportunity for human error.

Cavu Biotherapies

Houston pet immunotherapy company, Cavu Biotherapies, has seen a tremendous amount of growth and is now a treatment partner at 43 clinic providers in 18 states and Canada. Founder Colleen O'Connor says she's seen a near 600 percent growth in revenue over the past year and treated 38 dog cancer patients in that timeframe.

CorInnova

Another Houston company, CorInnova, has created a device from a soft, flexible material that can be easily inserted through a 1-inch incision, and then be used for increase blood pumping in the heart by 50 percent.

Hive Genie

Houston-based Hive Genie is using technology to help beekeepers optimize their pollination operations and monitor hive operations remotely. Gone are the days, Hive Genie hopes, that beekeepers need to suit up to track and maintain their colonies physically.

Siera AI

Austin-based Siera AI is using its AI-enabled cloud IoT platform for logistics solutions and safety improvements in warehouse settings. A goal of the company's, according to its website, is to free humans from these types of dull, dangerous, dirty tasks.

Skycom

The sky's not even the limit for Austin-based Skycom and its airship technology that supplies low-cost cell towers in orbit. The technology can bring down the cost of mobile service providers and allow for growth into new markets.

Tevido

Another Austin company, Tevido uses a pigment cell graft process to use patients' own skin cells to restore normal skin color for patients with vitiligo and pale scars.

Tot Squad

Los Angeles-based Tot Squad emerged as a service-focused company for baby-related tasks and now has emerged as a digital marketplace connecting service providers online to parents and to-be parents for needs like stroller cleaning or carseat installation.

With the Texas Medical Center in their backyard, these Houston biotech companies are creating breakthrough technologies. Getty Images

5 Houston biotech companies taking health care to new levels

The future is now

Houston is the home of the largest medical center in the world, so it comes as no surprise that the Bayou City is also home to breakthrough technologies. Here are five Houston companies developing some of this biotech advancements.

Moleculin Biotech Inc.

Houston-based Moleculin has three different oncology technologies currently in trials. Getty Images

Immunotherapy and personalized medicine get all the headlines lately, but in the fight against cancer, a natural compound created by bees could beat them in winning one battle.

In 2007, chairman and CEO Walter Klemp founded Moleculin Biotech Inc. as a private company. The former CPA had found success in life sciences with a company that sold devices for the treatment of acne. That introduction into the field of medical technology pushed him toward more profound issues than spotty skin.

"Coincidentally, the inventor of that technology had a brother who was a neuro-oncologist at MD Anderson," Klemp recalls.

The since-deceased Dr. Charles Conrad slowly lured Klemp into what he calls the "cancer ecosphere" of MD Anderson. In 2016, the company went public. And it looks like sooner rather than later, it could make major inroads against some of the toughest cancers to beat. Read the full story here.

Cavu Biotherapies

Dr. Colleen O'Connor has adapted immunotherapy treatments to be used in dogs. Courtesy of CAVU Biotherapies

Breakthrough biotech doesn't have to just be for humans. More than three years after its founding, Houston-based veterinary biotech company CAVU Biotherapies' had its first cancer patient: a black Labrador in Pennsylvania diagnosed with B-cell lymphoma.

Dr. Colleen O'Connor, CEO and founder of CAVU Biotherapies, established the company in July 2015 with a goal to help pets live longer post-cancer diagnoses. O'Connor, who earned a PhD in toxicology with a specialty in immunology, has more than a decade of hands-on experience researching cancer treatments.

"Our goal is to scale up and be able to increase our dogs' qualities of life with us," O'Connor said. "We want to keep families intact longer and we want to be able to modernize cancer care for our animals." Read the full story here.

Innovative Biochips

iBiochips, led by founder Lidong Qin, was awarded a $1.5 million grant in September to help develop a new technology that delivers data about the cell's genetic makeup and reports abnormalities. Courtesy of Lidong Qin

Innovative Biochips, a Houston-based biotechnology company, is one step closer to commercializing technology that the company hopes will provide an opportunity for researchers to detect diseases earlier.

The company was founded three years ago by Dr. Lidong Qin, a professor at the Houston Methodist Research Institute's department of nanomedicine. He launched iBiochips as an independent faculty startup that licensed technology from Houston Methodist. Qin says he wanted to engineer and manufacture devices that focus on revolutionizing single-cell isolation and genetic analysis. Read the full story here.

Celltex

Celltex's stem cell technology has received positive results from its multiple sclerosis, Parkinson's, and rheumatoid arthritis patients. Courtesy of Celltex

A Houston stem cell company is making strides in regenerative medicine. Celltex's treatment has been proved effective with its patients. Eighty-three percent of multiple sclerosis patients have reported improvement of symptoms specific to their disease, as have 73 percent of Parkinson's sufferers. But the staggering fact is that 100 percent of 58 respondents with rheumatoid arthritis say they have benefited.

David Eller, chairman, co-founder and CEO of the company, also recently announced the company's expansion to Saudi Arabia. Read the full story here.

Ridgeline Therapeutics

Houston-based Ridgeline Therapeutics isn't going to allow you beat aging, but someday it may well help you to live without muscle loss or diabetes. Getty Images

Stan Watowich pictures a world where elderly people have the same healthy muscles they had at a younger age. Watowich is CEO of Ridgeline Therapeutics, a spin-off company of the University of Texas Medical Branch in Galveston where he is an associate professor of biochemistry and molecular biology, and he wants to make it clear that he is not going to cure aging.

"You and I are still going to get old," he says. "But we have our hopes that as we get old our muscles will stay healthy."

He's talking about the drug candidate, RLT-72484. It has been shown to reactivate muscle stem cells and regenerate skeletal muscle in aged laboratory mice. Read the full story here.


Armed with their doctorate degrees and startups, these three STEM biotech innovators are going places. Courtesy photos

3 Houston heath tech innovators to know this week

Who's Who

Whether it's for dogs or dating, Houston is prime for innovative leaders in health science startups, and there are three in particular you need to know going into a new week. From a DNA-based dating app creator and a researcher curing cancer in dogs to cutting-edge biotech leader, here are the Houston innovators to know. Doctorate degrees and startup companies in hand, each of these entrepreneurs is going places.

Brittany Barreto, co-founder and CEO of Pheramor

Courtesy of Pheramor

Brittany Barreto was studying genetics in college, and her professor was talking about how there are 11 genes in DNA that can determine physical compatibility with others. She had the idea right then and there in the classroom to make a DNA-based dating app. Almost 10 years later, she's done it, with Pheramor.

The Houston startup has launched nationwide and is in the midst of another capital campaign. Barreto is also looking to expand her team to account for the growth and success.

Lidong Qin, founder of Innovative Biochips

Courtesy of Lidong Qin

Lidong Qin spends his days as a professor at the Houston Methodist Research Institute's department of nanomedicine, but three years ago, he expanded his resume. He launched his biotech startup, Innovative Biochips, as an independent faculty startup that licensed technology from Houston Methodist.

Qin says it can be difficult to launch a biotech startup in Houston, since the industry requires hefty initial funds to open a facility, get patents and hire a team of researchers. Now, iBiochips is armed with private investments and a $1.5 million grant from the National Institutes of Health's Small Business Technology Transfer program to continue researching and developing early disease detection technologies.

Colleen O'Connor, founder of CAVU Biotherapies 

CAVU Colleen O'Connor

Courtesy of CAVU Biotherapies

Losing a pet is awful, and for so many people, pets are full-blown family members. When Colleen O'Connor lost her furry family members to cancer, she knew she had to do something about it. Cancer treatment in humans had evolved to include immunotherapy, and O'Connor thought man's best friend deserved an upgrade from the 1980s practices veterinarians use.

She created Houston-based CAVU Biotherapies, and, in September, the first treatment was administered to a black lab named Franklin. O'Connor is focused on expanding her treatment and its access to pups so that no pet owner has to prematurely say goodbye to good boys and girls.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Rice Business Plan Competition names startup teams for 2026 event

ready, set, pitch

The Rice Alliance for Technology and Entrepreneurship has announced the 42 student-led teams that will compete in the 26th annual Rice Business Plan Competition this spring.

The highly competitive event, known as one of the world’s largest and richest intercollegiate student startup challenges, will take place April 9-11 on Rice's campus and at the Ion. Teams in this year's competition represent 39 universities from four countries, including one team from Rice and two from the University of Texas at Austin.

Graduate student-led teams from colleges or universities around the world will present their plans before more than 300 angel, venture capital and corporate investors to compete for more than $1 million in prizes. Top teams were awarded $2 million in investment and cash prizes at the 2025 event.

The 2026 invitees include:

  • Alchemll, University of Tennessee - Knoxville
  • Altaris MedTech, University of Arkansas
  • Armada Therapeutics, Dartmouth College
  • Arrow Analytics, Texas A&M University
  • Aura Life Science, Northwestern University
  • BeamFeed, City University of New York
  • BiliRoo, University of Michigan
  • BioLegacy, Seattle University
  • BlueHealer, Johns Hopkins University
  • BRCĒ, Michigan State University
  • ChargeBay, University of Miami
  • Cocoa Potash, Case Western Reserve
  • Cosnetix, Yale University
  • Cottage Core, Kent State University
  • Crack'd Up, University of Wisconsin - Madison
  • Curbon, Princeton University
  • DialySafe, Rice University
  • Foregger Energy Systems, Babson College
  • Forge, University of California, Berkeley
  • Grapheon, University of Pittsburgh
  • GUIDEAIR Labs, University of Washington
  • Hydrastack, University of Chicago
  • Imagine Devices, University of Texas at Austin
  • Innowind Energy Solutions, University of Waterloo (Canada)
  • JanuTech, University of Washington
  • Laetech, University of Toronto (Canada)
  • Lectra Technologies, MIT
  • Legion Platforms, Arizona State University
  • Lucy, University of Pennsylvania
  • NerView Surgical, McMaster University (Canada)
  • Panoptica Technologies, Georgia Tech University
  • PowerHouse, MIT
  • Quantum Power Systems, University of Texas at Austin
  • Routora, University of Notre Dame
  • Sentivity.ai, Virginia Tech
  • Shinra Energy, Harvard University
  • Solid Air Dynamics, RWTH Aachen (Germany)
  • Spine Biotics, University of North Carolina - Chapel Hill
  • The Good Company, Michigan Tech
  • UNCHAIN, Lehigh University
  • VivoFlux, University of Rochester
  • Vocadian, University of Oxford (UK)

This year's group joins more than 910 RBPC alums that have raised more than $6.9 billion in capital, according to Rice.

The University of Michigan's Intero Biosystems, which is developing the first stem cell-driven human “mini gut,” took home the largest investment sum of $902,000 last year. The company also claimed the first-place prize.

Houston suburb ranks as No. 3 best place to retire in Texas

Rankings & Reports

Texas retirees on the hunt for the right place to settle down and enjoy their blissful retirement years will find their haven in the Houston suburb of Pasadena, which just ranked as the third-best city to retire statewide.

A new study conducted by the research team at RetirementLiving.com, "The Best Cities to Retire in Texas," compared the affordability, safety, livability, and healthcare access for seniors across 31 Texas cities with at least 90,000 residents.

Wichita Falls, about 140 miles northwest of Dallas, claimed the top spot as the No. 1 best place to retire in Texas.

The senior living experts said Pasadena has the best healthcare access for seniors in the entire state, and it ranked as the No. 8 most affordable city on the list.

"Taking care of one’s health can be stressful for seniors," the report said. "Harris County, where [Pasadena is] located, has 281.1 primary care physicians per 1,000 seniors — that’s almost 50-fold the statewide ratio of 5.9 per 1,000."

Pasadena ranked 10th overall for its livability, and ranked 25th for safety, the report added.

Meanwhile, Houston proper ranked as the No. 31 best place to retire in Texas, but its livability score was the 7th best statewide.

Seven of the Lone Star State's top 10 best retirement locales are located in the Dallas-Fort Worth Metroplex: Carrollton (No. 2), Plano (No. 4), Garland (No. 5), Richardson (No. 6), Arlington (No. 7), Grand Prairie (No. 8), and Irving (No. 9). McAllen, a South Texas border town, rounded out the top 10.

RetirementLiving said Carrollton has one of the lowest property and violent crime rates per capita in Texas, and it ranked as the No. 5 safest city on the list. About 17 percent of the city's population is aged 65 or older, which is higher than the statewide average of just 14 percent.

The top 10 best place to retire in Texas in 2026 are:

  • No. 1 – Wichita Falls
  • No. 2 – Carrollton
  • No. 3 – Pasadena
  • No. 4 – Plano
  • No. 5 – Garland
  • No. 6 – Richardson
  • No. 7 – Arlington
  • No. 8 – Grand Prairie
  • No. 9 – Irving
  • No. 10 – McAllen
---

This article originally appeared on CultureMap.com.

Rice University lands $18M to revolutionize lymphatic disease detection

fresh funding

An arm of the U.S. Department of Health and Human Services has awarded $18 million to scientists at Rice University for research that has the potential to revolutionize how lymphatic diseases are detected and help increase survivability.

The lymphatic system is the network of vessels all over the body that help eliminate waste, absorb fat and maintain fluid balance. Diseases in this system are often difficult to detect early due to the small size of the vessels and the invasiveness of biopsy testing. Though survival rates of lymph disease have skyrocketed in the United States over the last five years, it still claims around 200,000 people in the country annually.

Early detection of complex lymphatic anomalies (CLAs) and lymphedema is essential in increasing successful treatment rates. That’s where Rice University’s SynthX Center, directed by Han Xiao and Lei Li, an assistant professor of electrical and computer engineering, comes in.

Aided by researchers from Texas Children’s Hospital, Baylor College of Medicine, the University of Texas at Dallas and the University of Texas Southwestern Medical Center, the center is pioneering two technologies: the Visual Imaging System for Tracing and Analyzing Lymphatics with Photoacoustics (VISTA-LYMPH) and Digital Plasmonic Nanobubble Detection for Protein (DIAMOND-P).

Simply put, VISTA-LYMPH uses photoacoustic tomography (PAT), a combination of light and sound, to more accurately map the tiny vessels of the lymphatic system. The process is more effective than diagnostic tools that use only light or sound, independent of one another. The research award is through the Advanced Research Projects Agency for Health (ARPA-H) Lymphatic Imaging, Genomics and pHenotyping Technologies (LIGHT) program, part of the U.S. HHS, which saw the potential of VISTA-LYMPH in animal tests that produced finely detailed diagnostic maps.

“Thanks to ARPA-H’s award, we will build the most advanced PAT system to image the body’s lymphatic network with unprecedented resolution and speed, enabling earlier and more accurate diagnosis,” Li said in a news release.

Meanwhile, DIAMOND-P could replace the older, less exact immunoassay. It uses laser-heated vapors of plasmonic nanoparticles to detect viruses without having to separate or amplify, and at room temperature, greatly simplifying the process. This is an important part of greater diagnosis because even with VISTA-LYMPH’s greater imaging accuracy, many lymphatic diseases still do not appear. Detecting biological markers is still necessary.

According to Rice, the efforts will help address lymphatic disorders, including Gorham-Stout disease, kaposiform lymphangiomatosis and generalized lymphatic anomaly. They also could help manage conditions associated with lymphatic dysfunction, including cancer metastasis, cardiovascular disease and neurodegeneration.

“By validating VISTA-LYMPH and DIAMOND-P in both preclinical and clinical settings, the team aims to establish a comprehensive diagnostic pipeline for lymphatic diseases and potentially beyond,” Xiao added in the release.

The ARPA-H award funds the project for up to five years.